Glenmark Pharmaceuticals announced that Lotus International, a wholly owned subsidiary of Lotus Pharmaceutical, has acquired the rights to commercialize Ryaltris olopatadine hydrochloride / mometasone furoate nasal spray in Singapore, Hong Kong and Vietnam. Lotus will make an upfront payment as well as future payments based on regulatory and sales milestones. Glenmark is already partnered on Ryaltris with Grand Pharmaceutical in China and Yuhan Corporation in South Korea.
Lotus CEO Petar Vazharov said, “As being strongly committed to making a difference for all patients, we are honored to partner with Glenmark to ensure this novel spray drug accessible to patients in southeast Asia. This is also the first brand product to be included in our respiratory portfolio with strong clinical data and IP protection. The partnership not only strengthens the competitiveness of our overall product portfolio but also accelerates our expansion in key SEA countries.”
Glenmark Pharmaceuticals Chief Commercial Officer Robert Crockart commented, “We are excited to partner with Lotus for Ryaltris as it is a strong and reputed player in the region and is aligned with Glenmark’s objective to provide quality novel products to fulfill unmet needs of patients with allergic rhinitis. This partnership will provide patients access to a highly effective and proven treatment for allergic rhinitis in these key South-East Asian markets.”
Ryaltris was recently approved for the treatment of seasonal allergic rhinitis in the US, where Hikma has the rights to market the nasal spray. Seqirus already markets the nasal spray in Australia. Menarini has the rights to market Ryaltris in 33 European countries, and Bausch Health has the Canadian rights.
Read the Glenmark Pharmaceuticals press release.
